Frazier Healthcare Partners

Selected news for the capital firm - Frazier Healthcare Partners, collected since 11/2017. Recent stories appear in HIT Consultant and The Wall Street Journal. This capital firm shares healthcare news with COVID-19, Eli Lilly, Biotech, OrbiMed and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/27/2021 PE Firm Frazier Healthcare Partners Closes $1.4B Growth Buyout Fund HIT Consultant Leave a CommentWhat You Should Know:– Frazier Healthcare Partners , a Seattle-based healthcare private equity firm announced the close of its tenth global buyouts fund and 13th fund across buyouts and life sciences. Investment focus will continue to be middle market provider-based businesses, with virtual health as a major component. The oversubscribed $1.4 billion fund, FHGB X, is significantly larger than FHGB IX, which closed at $780M ...
5/27/2021 Frazier Healthcare Partners Raises $1.4 Billion The Wall Street Journal Frazier Healthcare Partners has raised $1.4 billion for its 10th fund to invest in the increasingly popular healthcare sector.The Seattle firm said it closed Frazier Healthcare Growth Buyout Fund X LP at its hard cap and that it was oversubscribed. The fund far surpasses its predecessor, which closed on $780 million in 2018. That vehicle is fully invested in nine companies, according to Nader Naini, a managing partner at ...
5/27/2021 Electronic Sequencing Platform GenapSys Raises $70 Million pulse2.com ... advancing GenapSys’ semiconductor based next-generation sequencing (NGS) platform. Plus Bob Zollars and a representative of Farallon Capital have been appointed to GenapSys’ Board of Directors. Zollars is a senior advisor at Frazier Healthcare Partners in their growth equity business. And previously, Zollars was group president at Cardinal Health and was responsible for 5 of their subsidiary companies, he also led 4 different operating divisions at Baxter Healthcare ...
5/27/2021 GenapSys Raises $70M in Series D Financing genomeweb.com ... at least $236 million since 2013, plus $75 million in debt funding last year. The firm offers its benchtop GenapSys Sequencer and a library preparation instrument.GenapSys is adding Bob Zollars, senior advisor at Frazier Healthcare Partners , and a representative of Farallon Capital to its board. Zollars was previously group president at Cardinal Health. He is also chair of the trustees of Arizona State University ...
5/20/2021 EPTAM acquires Minnesota medical component maker nhbr.com ... customers with a “one-stop shop” for orthopedic, cardiovascular, minimally invasive surgery and robotic-assisted surgery components.No transaction price was provided.Founded in 1981, EPTAM itself was acquired in January 2020 by Frazier Healthcare Partners . It specializes in polymer machining, precision metal machining and injection molding. It has over 450 employees and has two other facilities besides Northfield, one in Colorado. Springs, Colo., and the other in Phillipsburg ...
5/18/2021 Hummingbird Bioscience buzzes with $150M series C led by Novo Holdings FierceBiotech ... focus on Asian life sciences investment.Novo was joined by Amgen Ventures, another investment fund run by a big pharma that has a strategic collaboration with Hummingbird for cancer research. Other new investors include Frazier Healthcare Partners and Octagon Capital, while existing investors SK Inc, Heritas Capital and others also contributed.Novo has followed the Singapore and U.S.-headquartered biotech's progress for several years, Partner Kenneth Harrison said in a ...
5/18/2021 Hummingbird Bioscience Raises US$125 Million in Series C Financing PR Newswire ... will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision therapeutics - Kenneth Harrison from Novo Ventures (an affiliate of Novo Holdings) and Dan Estes from Frazier Healthcare Partners to join Board of Directors SINGAPORE, May 17, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today ...
5/18/2021 Hummingbird Bioscience Raises US$125 Million in Series C Financing prnasia.com ... will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision therapeutics Kenneth Harrison from Novo Ventures (an affiliate of Novo Holdings) and Dan Estes from Frazier Healthcare Partners to join Board of DirectorsSINGAPORE Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced the close of ...
5/18/2021 Hummingbird Bioscience Raises US$125 Million in Series C Financing Yahoo News ... will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision therapeutics Kenneth Harrison from Novo Ventures (an affiliate of Novo Holdings) and Dan Estes from Frazier Healthcare Partners to join Board of Directors SINGAPORE, May 18, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today ...
5/18/2021 Hummingbird Bioscience Raises US$125 Million in Series C Financing asianpolyglotview.com ... support advancement of Hummingbird’s lead assets in clinical trials and building of its next-generation portfolio of precision therapeutics Kenneth Harrison from Novo Ventures (an affiliate of Novo Holdings) and Dan Estes from Frazier Healthcare Partners to join Board of DirectorsSINGAPORE , May 17, 2021 /PRNewswire/ — Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes ...
5/18/2021 Singapore biotherapeutics firm Hummingbird bags $125m in series C round techinasia.com Hummingbird Bioscience , a Singapore-based company focused on antibody discovery, pharmacology, and clinical development, has raised US$125 million in its latest round of funding.More funding details Lead investor : Novo Holdings Other investors: Frazier Healthcare Partners , Octagon Capital, EDBI, Amgen Ventures, Droia Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group, and Altrium Capital Management Returning investors: SK, Heritas Capital, and Mirae Asset Venture Capital ...
5/18/2021 Hummingbird Bioscience Raises US$125M in Series C Financing finsmes.com ... on developing precision therapies against hard-to-drug targets to improve treatment outcomes, closed a US$125m Series C financing round.The round was led by Novo Holdings, with participation from new investors including Frazier Healthcare Partners , Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset ...
5/18/2021 Hummingbird Bioscience Raises US$125 Million in Series C Financing intellasia.net ... will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision therapeutics Kenneth Harrison from Novo Ventures (an affiliate of Novo Holdings) and Dan Estes from Frazier Healthcare Partners to join Board of DirectorsSINGAPORE , May 18, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today ...
5/17/2021 Hummingbird Bioscience Raises US$125 Million in Series C Financing | Markets Insider Business Insider ... to-drug targets to improve treatment outcomes, today announced the close of its US$125 million Series C financing round. The financing was led by Novo Holdings, with significant participation from new investors including Frazier Healthcare Partners , Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management. Existing investors including SK Inc, Heritas Capital, and Mirae Asset ...
5/17/2021 Hummingbird Bioscience Raises US$125 Million in Series C Financing | Markets Insider Business Insider ... to-drug targets to improve treatment outcomes, today announced the close of its US$125 million Series C financing round. The financing was led by Novo Holdings, with significant participation from new investors including Frazier Healthcare Partners , Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management. Existing investors including SK Inc, Heritas Capital, and Mirae Asset ...
5/17/2021 Investment round led by Novo Holdings, joined by a wapakdailynews.com ... will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision therapeutics Kenneth Harrison from Novo Ventures (an affiliate of Novo Holdings) and Dan Estes from Frazier Healthcare Partners to join Board of Directors SINGAPORE Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced the close of ...
5/6/2021 Edgemont Partners Advises Spine Nevada on Partnership with HOPCo | Financial Buzz financialbuzz.com ... programs, Swift Urgent Clinic and Vein Nevada (collectively “Spine Nevada”), on its recapitalization transaction with Healthcare Outcomes Performance Company (“HOPCo”). HOPCo’s private equity investors include Audax Private Equity, Linden Capital, and Frazier Healthcare Partners . Spine Nevada provides comprehensive musculoskeletal care throughout Nevada, with 14 locations in Reno, Carson City and Las Vegas. The Company provides services inclusive of spine, neurology, orthopedics, urgent care clinics, imagining centers, and ...
5/6/2021 Edgemont Partners Advises Spine Nevada on Partnership with HOPCo | Financial Buzz financialbuzz.com ... programs, Swift Urgent Clinic and Vein Nevada (collectively “Spine Nevada”), on its recapitalization transaction with Healthcare Outcomes Performance Company (“HOPCo”). HOPCo’s private equity investors include Audax Private Equity, Linden Capital, and Frazier Healthcare Partners . Spine Nevada provides comprehensive musculoskeletal care throughout Nevada, with 14 locations in Reno, Carson City and Las Vegas. The Company provides services inclusive of spine, neurology, orthopedics, urgent care clinics, imaging centers, and ...
5/6/2021 Edgemont Partners Advises Spine Nevada on Partnership with HOPCo | Business Wire Business Wire ... programs, Swift Urgent Clinic and Vein Nevada (collectively “Spine Nevada”), on its recapitalization transaction with Healthcare Outcomes Performance Company (“HOPCo”). HOPCo’s private equity investors include Audax Private Equity, Linden Capital, and Frazier Healthcare Partners . Spine Nevada provides comprehensive musculoskeletal care throughout Nevada, with 14 locations in Reno, Carson City and Las Vegas. The Company provides services inclusive of spine, neurology, orthopedics, urgent care clinics, imaging centers, and ...
5/6/2021 Edgemont Partners Advises Spine Nevada on Partnership with HOPCo Yahoo News ... its affiliated programs, Swift Urgent Clinic and Vein Nevada (collectively "Spine Nevada"), on its recapitalization transaction with Healthcare Outcomes Performance Company ("HOPCo"). HOPCo’s private equity investors include Audax Private Equity, Linden Capital, and Frazier Healthcare Partners . Spine Nevada provides comprehensive musculoskeletal care throughout Nevada, with 14 locations in Reno, Carson City and Las Vegas. The Company provides services inclusive of spine, neurology, orthopedics, urgent care clinics, imaging centers, and ...